Ramida WatanapokasinDuangmanee SanmundPranee WinichagoonKoichiro MutaSuthat FucharoenSrinakharinwirot UniversityThe Institute of Science and Technology for Research and Development, Mahidol UniversityKyushu University, Faculty of Medical Sciences2018-08-202018-08-202006-03-01Annals of Hematology. Vol.85, No.3 (2006), 164-169093955552-s2.0-31744445922https://repository.li.mahidol.ac.th/handle/20.500.14594/23809Due to genetic heterogeneity of β-thalassemia (β-thal) patients, several efforts have been undertaken to determine the efficacy of hydroxyurea treatment. The aim of this work is to determine the responder and nonresponder for hydroxyurea treatment in β-thal intermedia based on γ-globin mRNA and fetal hemoglobin (HbF) induction in human erythroid progenitor cells purified from a patient's peripheral blood. Eighteen β-thal/hemoglobin E patients [13 βE/codon41/42(-TCTT), 4 βE/codon17, and 1 βE/IVS-654], requiring blood transfusion occasionally, with Hb levels of 5.20-8.50 g/dl were studied. The relative levels of γ-globin mRNA was measured by real-time reverse-transcription polymerase chain reaction and HbF by high-performance liquid chromatography. The results indicated that erythroid progenitor cells treated with 30 μmol/l hydroxyurea for 96 h preferentially enhancedGγ-andAγ-globin mRNA. The mean values ofGγ-globin mRNA fold induction were higher thanAγ-globin mRNA (12±4 vs 4±0.30), the Pearson's correlation ofGγ-andAγ- globin mRNA was r=0.80. Induction ofGγ/Aγ globin mRNA is up to ninefold. A 30% increase in the proportion of HbF out of the total Hb was found in cultures derived from four patients, 20-30% in cultures from nine patients, and less than 20% in cultures from five patients. In cultures from only two patients, increase in the proportion of HbF was less than 3%, andGγ/Aγ globin mRNA is less than 0.50. © Springer-Verlag 2006.Mahidol UniversityMedicineArticleSCOPUS10.1007/s00277-005-0049-1